pDNA-PK levels are decreased in absence of cGAS. by Elona Gusho (4688170)

Organizational benefits. by Fabrizio Schettini (12009517)

Subjects:

Proportion of individuals’ general benefits scores that increased, decreased, or remained unchanged between time points. by Jessie B. Moore (12578140)

Both MRI and SR-PCI demonstrated significant decreases in clinically-relevant articular cartilage parameters. by Suranjan Bairagi (17087667)

Significant main effect of housing type. by Grace Hecker (18813445)

Subjects:

Significant interactions and main effects of day. by Grace Hecker (18813445)

Subjects:

Behaviors with a significant main effect or interaction. by Grace Hecker (18813445)

Subjects:

RNA Seq Significant Genes from Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma by David M. Woods (15010641)

Visual benefit and visual degradation at far. by Shrilekha Vedhakrishnan (12256977)

Subjects:

cGAS exacerbates <i>Schistosoma japonicum</i> infection in mice. by Le Liang (2144725)

Number of participants showing improved, decreased, or no change in task performance with and without PSAPs. by Maxime Perron (16618003)

Variants with an unknown significance or conflicting interpretation of clinical significance. by J. Tyson McDonald (3687694)

Subjects:

cGAS is required for an ISD, but not an LPS, -induced type I IFN response. by Le Liang (2144725)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Giving credit to reforestation for water quality benefits - Fig 5 by Arturo A. Keller (119450)

Summary of risks, benefits, and examples of commercial products for major microbial genes. by Saiko Sugita (14581134)

TFFs are decreased in serum but not urine samples from Nigerian children infected with <i>S</i>. <i>haematobium</i>. by Babatunde Adewale (11576954)

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)